Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Targeted Drug ALK Inhibitors for NSCLC market report explains the definition, types, applications, major countries, and major players of the Targeted Drug ALK Inhibitors for NSCLC market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Novartis
Chugai Pharmaceutical (Hoffmann-La Roche group)
Beacon Pharma Limited
Genvio Pharma Limited
ARIAD Pharmaceuticals (Takeda)
Drug International Limted
Incepta Pharmaceuticals
Pfizer
By Type:
Crizotinib
Ceritinib
Alectinib
Brigatinib
Lorlatinib
Other
By End-User:
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Targeted Drug ALK Inhibitors for NSCLC Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Targeted Drug ALK Inhibitors for NSCLC Outlook to 2028- Original Forecasts
-
2.2 Targeted Drug ALK Inhibitors for NSCLC Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Targeted Drug ALK Inhibitors for NSCLC Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Targeted Drug ALK Inhibitors for NSCLC Market- Recent Developments
-
6.1 Targeted Drug ALK Inhibitors for NSCLC Market News and Developments
-
6.2 Targeted Drug ALK Inhibitors for NSCLC Market Deals Landscape
7 Targeted Drug ALK Inhibitors for NSCLC Raw Materials and Cost Structure Analysis
-
7.1 Targeted Drug ALK Inhibitors for NSCLC Key Raw Materials
-
7.2 Targeted Drug ALK Inhibitors for NSCLC Price Trend of Key Raw Materials
-
7.3 Targeted Drug ALK Inhibitors for NSCLC Key Suppliers of Raw Materials
-
7.4 Targeted Drug ALK Inhibitors for NSCLC Market Concentration Rate of Raw Materials
-
7.5 Targeted Drug ALK Inhibitors for NSCLC Cost Structure Analysis
-
7.5.1 Targeted Drug ALK Inhibitors for NSCLC Raw Materials Analysis
-
7.5.2 Targeted Drug ALK Inhibitors for NSCLC Labor Cost Analysis
-
7.5.3 Targeted Drug ALK Inhibitors for NSCLC Manufacturing Expenses Analysis
8 Global Targeted Drug ALK Inhibitors for NSCLC Import and Export Analysis (Top 10 Countries)
-
8.1 Global Targeted Drug ALK Inhibitors for NSCLC Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Targeted Drug ALK Inhibitors for NSCLC Export by Region (Top 10 Countries) (2017-2028)
9 Global Targeted Drug ALK Inhibitors for NSCLC Market Outlook by Types and Applications to 2022
-
9.1 Global Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Crizotinib Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Ceritinib Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Alectinib Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Brigatinib Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Lorlatinib Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Other Consumption and Growth Rate (2017-2022)
-
9.2 Global Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Targeted Drug ALK Inhibitors for NSCLC Market Analysis and Outlook till 2022
-
10.1 Global Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.2.2 Canada Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.2.3 Mexico Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.2 UK Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.3 Spain Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.4 Belgium Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.5 France Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.6 Italy Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.7 Denmark Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.8 Finland Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.9 Norway Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.10 Sweden Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.11 Poland Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.12 Russia Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.3.13 Turkey Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.2 Japan Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.3 India Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.4 South Korea Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.5 Pakistan Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.6 Bangladesh Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.7 Indonesia Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.8 Thailand Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.9 Singapore Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.10 Malaysia Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.11 Philippines Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.4.12 Vietnam Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.2 Colombia Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.3 Chile Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.4 Argentina Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.5 Venezuela Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.6 Peru Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.7 Puerto Rico Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.5.8 Ecuador Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6.2 Kuwait Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6.3 Oman Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6.4 Qatar Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6.5 Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.6.6 United Arab Emirates Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.7.2 South Africa Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.7.3 Egypt Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.7.4 Algeria Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
10.8.2 New Zealand Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
11 Global Targeted Drug ALK Inhibitors for NSCLC Competitive Analysis
-
11.1 Novartis
-
11.1.1 Novartis Company Details
-
11.1.2 Novartis Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
11.1.4 Novartis Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Chugai Pharmaceutical (Hoffmann-La Roche group)
-
11.2.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
-
11.2.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
11.2.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Beacon Pharma Limited
-
11.3.1 Beacon Pharma Limited Company Details
-
11.3.2 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
11.3.4 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Genvio Pharma Limited
-
11.4.1 Genvio Pharma Limited Company Details
-
11.4.2 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
11.4.4 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 ARIAD Pharmaceuticals (Takeda)
-
11.5.1 ARIAD Pharmaceuticals (Takeda) Company Details
-
11.5.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
11.5.4 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Drug International Limted
-
11.6.1 Drug International Limted Company Details
-
11.6.2 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
11.6.4 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Incepta Pharmaceuticals
-
11.7.1 Incepta Pharmaceuticals Company Details
-
11.7.2 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
11.7.4 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Pfizer
-
11.8.1 Pfizer Company Details
-
11.8.2 Pfizer Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
11.8.4 Pfizer Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
11.8.5 Recent Research and Development Strategies
12 Global Targeted Drug ALK Inhibitors for NSCLC Market Outlook by Types and Applications to 2028
-
12.1 Global Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Crizotinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Ceritinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Alectinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Brigatinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Lorlatinib Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Other Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Targeted Drug ALK Inhibitors for NSCLC Market Analysis and Outlook to 2028
-
13.1 Global Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.2.2 Canada Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.2.3 Mexico Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.2 UK Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.3 Spain Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.4 Belgium Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.5 France Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.6 Italy Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.7 Denmark Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.8 Finland Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.9 Norway Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.10 Sweden Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.11 Poland Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.12 Russia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.3.13 Turkey Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.2 Japan Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.3 India Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.4 South Korea Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.8 Thailand Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.9 Singapore Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.11 Philippines Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.2 Colombia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.3 Chile Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.4 Argentina Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.6 Peru Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6.3 Oman Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6.4 Qatar Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.7.2 South Africa Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.7.3 Egypt Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.7.4 Algeria Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Targeted Drug ALK Inhibitors for NSCLC
-
Figure of Targeted Drug ALK Inhibitors for NSCLC Picture
-
Table Global Targeted Drug ALK Inhibitors for NSCLC Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Targeted Drug ALK Inhibitors for NSCLC Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Crizotinib Consumption and Growth Rate (2017-2022)
-
Figure Global Ceritinib Consumption and Growth Rate (2017-2022)
-
Figure Global Alectinib Consumption and Growth Rate (2017-2022)
-
Figure Global Brigatinib Consumption and Growth Rate (2017-2022)
-
Figure Global Lorlatinib Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Targeted Drug ALK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Table North America Targeted Drug ALK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure United States Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Canada Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Mexico Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Europe Targeted Drug ALK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure Germany Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure UK Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Spain Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Belgium Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure France Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Italy Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Denmark Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Finland Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Norway Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Sweden Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Poland Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Russia Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Turkey Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table APAC Targeted Drug ALK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure China Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Japan Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure India Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure South Korea Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Thailand Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Singapore Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Philippines Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table South America Targeted Drug ALK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure Brazil Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Colombia Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Chile Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Argentina Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Peru Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table GCC Targeted Drug ALK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure Bahrain Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Oman Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Qatar Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Africa Targeted Drug ALK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure Nigeria Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure South Africa Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Egypt Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Algeria Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Oceania Targeted Drug ALK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure Australia Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Novartis Company Details
-
Table Novartis Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
Table Novartis Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
Table Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
-
Table Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
Table Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
Table Beacon Pharma Limited Company Details
-
Table Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
Table Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
Table Genvio Pharma Limited Company Details
-
Table Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
Table Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
Table ARIAD Pharmaceuticals (Takeda) Company Details
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
Table Drug International Limted Company Details
-
Table Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
Table Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
Table Incepta Pharmaceuticals Company Details
-
Table Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
Table Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Targeted Drug ALK Inhibitors for NSCLC Main Business and Markets Served
-
Table Pfizer Targeted Drug ALK Inhibitors for NSCLC Product Portfolio
-
Figure Global Crizotinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ceritinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Alectinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Brigatinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lorlatinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Table North America Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure United States Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Germany Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure China Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Brazil Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure Australia Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
